

# Stephen D Schmidt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5881572/publications.pdf>

Version: 2024-02-01

29  
papers

12,656  
citations

218677

26  
h-index

477307

29  
g-index

32  
all docs

32  
docs citations

32  
times ranked

16615  
citing authors

#	ARTICLE	IF	CITATIONS
1	An mRNA Vaccine against SARS-CoV-2 – Preliminary Report. <i>New England Journal of Medicine</i> , 2020, 383, 1920-1931.	27.0	2,719
2	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. <i>Science</i> , 2010, 329, 856-861.	12.6	1,600
3	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. <i>New England Journal of Medicine</i> , 2020, 383, 2427-2438.	27.0	1,242
4	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	27.0	936
5	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. <i>Nature</i> , 2011, 480, 336-343.	27.8	794
6	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014, 509, 55-62.	27.8	681
7	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. <i>New England Journal of Medicine</i> , 2021, 384, 80-82.	27.0	665
8	Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2259-2261.	27.0	603
9	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 1372-1377.	12.6	459
10	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. <i>New England Journal of Medicine</i> , 2022, 386, 1088-1091.	27.0	338
11	Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. <i>Nature</i> , 2014, 514, 642-645.	27.8	308
12	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. <i>Nature</i> , 2016, 533, 105-109.	27.8	281
13	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. <i>Science</i> , 2017, 358, 85-90.	12.6	225
14	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. <i>Science Translational Medicine</i> , 2014, 6, 243ra88.	12.4	222
15	Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization. <i>Science</i> , 2013, 340, 751-756.	12.6	213
16	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016, 90, 76-91.	3.4	205
17	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	28.9	179
18	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021, 373, .	12.6	174

#	ARTICLE	IF	CITATIONS
19	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	27.8	117
20	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	106
21	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015, 89, 5895-5903.	3.4	92
22	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	87
23	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	12.6	83
24	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. <i>Journal of Virology</i> , 2016, 90, 1321-1332.	3.4	68
25	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. <i>Cell Reports</i> , 2018, 22, 1798-1809.	6.4	52
26	Pathogenicity and Mucosal Transmissibility of the R5-Tropic Simian/Human Immunodeficiency Virus SHIV <sub>AD8</sub> in Rhesus Macaques: Implications for Use in Vaccine Studies. <i>Journal of Virology</i> , 2012, 86, 8516-8526.	3.4	47
27	Potent anti-viral activity of a trispesific HIV neutralizing antibody in SHIV-infected monkeys. <i>Cell Reports</i> , 2022, 38, 110199.	6.4	19
28	Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults. <i>JCI Insight</i> , 2022, 7, .	5.0	16
29	Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals. <i>Journal of Clinical Investigation</i> , 2019, 129, 4832-4837.	8.2	11